Get started
Author

Joyce Zhan

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
2020 · Samit R. Joshi, Disala Fernando, et al. · Pharmacology Research & Perspectives · 27
PDF
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
2022 · Christoph D Spinner, Franco Felizarta, et al. · Clinical Infectious Diseases · 21
PDF
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
2021 · Teodora Pene Dumitrescu, Samit R. Joshi, et al. · Antimicrobial Agents and Chemotherapy · 17
Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling
2022 · Bo Wen, Ying Zhang, et al. · Drug Metabolism and Disposition · 15
PDF
Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
2022 · Mark Johnson, Teodora Pene Dumitrescu, et al. · Clinical Pharmacology in Drug Development · 7
Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants
2023 · Ying Zhang, Mark Johnson, et al. · British Journal of Clinical Pharmacology · 5
PDF
OP29 Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in Ulcerative Colitis: Results from the ANTHEM-UC study
2026 · E Louis, V Jairath, et al. · Journal of Crohn s and Colitis · 1
S1449 Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial
2025 · Vipul Jairath, Britta Siegmund, et al. · The American Journal of Gastroenterology · 1
Effects of the HIV ‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
2023 · Ying Zhang, Mark Bush, et al. · Pharmacology Research & Perspectives · 1
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis
2026 · Maria T. Abreu, Britta Siegmund, et al. · New England Journal of Medicine
P171 Efficacy and safety of icotrokinra, a targeted oral peptide that blocks il-23 receptor activation, in ulcerative colitis: results from ANTHEM-UC
2026 · Jimmy Limdi, Vipul Jairath, et al. · E-Posters
27 Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastroenterology
487 Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastrointestinal Endoscopy
487 Efficacy of Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastroenterology
27 Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastrointestinal Endoscopy
Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults
2023 · Ying Zhang, Samit Joshi, et al. · British Journal of Clinical Pharmacology
PDF
Works count: 16
Citation count: 95
H-index: 5
I10-index: 4
Year
Topic
Type